| Literature DB >> 31649516 |
R L van den Brink1, T Pfeffer1, T H Donner1,2,3.
Abstract
Brain activity fluctuates continuously, even in the absence of changes in sensory input or motor output. These intrinsic activity fluctuations are correlated across brain regions and are spatially organized in macroscale networks. Variations in the strength, topography, and topology of correlated activity occur over time, and unfold upon a backbone of long-range anatomical connections. Subcortical neuromodulatory systems send widespread ascending projections to the cortex, and are thus ideally situated to shape the temporal and spatial structure of intrinsic correlations. These systems are also the targets of the pharmacological treatment of major neurological and psychiatric disorders, such as Parkinson's disease, depression, and schizophrenia. Here, we review recent work that has investigated how neuromodulatory systems shape correlations of intrinsic fluctuations of large-scale cortical activity. We discuss studies in the human, monkey, and rodent brain, with a focus on non-invasive recordings of human brain activity. We provide a structured but selective overview of this work and distil a number of emerging principles. Future efforts to chart the effect of specific neuromodulators and, in particular, specific receptors, on intrinsic correlations may help identify shared or antagonistic principles between different neuromodulatory systems. Such principles can inform models of healthy brain function and may provide an important reference for understanding altered cortical dynamics that are evident in neurological and psychiatric disorders, potentially paving the way for mechanistically inspired biomarkers and individualized treatments of these disorders.Entities:
Keywords: acetycholine; brainstem; dopamine; functional connectivity; neuromodulation; norepinepherine; resting-state; serotonin
Year: 2019 PMID: 31649516 PMCID: PMC6794422 DOI: 10.3389/fnhum.2019.00340
Source DB: PubMed Journal: Front Hum Neurosci ISSN: 1662-5161 Impact factor: 3.169
FIGURE 1Schematic of major neuromodulatory systems. Cerebellar, spinal, and temporal projections are omitted for brevity. The inset shows the approximate anatomical location of each nucleus that sends major afferents to the forebrain.
FIGURE 2Overview of cortical distributions of genetic expression of neuromodulator receptors in the human brain. Receptor maps were taken from Gryglewski et al. (2018), projected onto the cortical surface, and Z-scored across space. Files and tool for plotting these maps can be found here: github.com/rudyvdbrink/receptormaps. Abbreviations: D: dopamine; ACh: acetylcholine; M: muscarinic; N: nicotinic; 5HT: serotonin; H: histamine.
Summary of main findings of (pharmacological) manipulation of catecholamines (NE and DA).
| PET (humans) | Dynamic causal modeling | Clonidine (α2 agonist) | Rest: reduced effective connectivity from PFC to thalamus, and to and from visual cortex. Attentional task: general increase in effective connectivity, with changes centered on parietal cortex. | |
| fMRI (humans) | Graph theoretic analysis | Sulpride (D2 antagonist) | Reduced metrics of global and local efficiency. | |
| fMRI (humans) | Seed-based correlation | L-DOPA (DA precursor) | Increased correlation between putamen and cerebellum and brainstem. Increased correlation between ventral striatum and vlPFC. Reduced correlation between DMN, and ventral striatum and caudate. | |
| fMRI (humans) | Seed-based correlation | Reboxetine (SNRI) | Reboxetine: reduced amygdala-OFC correlation, and reduced striatal–OFC correlation. | |
| fMRI (humans) | Dual regression | Haloperidol (D2 antagonist) L-DOPA (DA precursor) | Linear increase (haloperidol < placebo < L-DOPA) between BG network and sensorimotor cortex. Inerted-U between BG network and dorsal anterior-mid cingulate (placebo > haloperidol and L-DOPA). Linear decrease (haloperidol > placebo > L-DOPA) between DMN and sensorimotor cortex. Linear increase (haloperidol < placebo < L-DOPA) between DMN and SMG. | |
| fMRI (humans) | Dual regression Seed-based correlation | Dexmedetomidine (α2 agonist) | Reduced correlation between DMN and bilateral thalamus and left cerebellum; increased correlation between DMN and IFG, putamen, and insula. Reduced correlation between rlFPN and cerebellum; increased correlation between rlFPN and cerebellum, precuneus, parietal operculum insula fusiform and angular gyri. Reduced correlation between llFPN and cerebellum, calcarine cortex, MFG, and SFG. | |
| fMRI (humans) | Seed-based correlation | Reboxetine (SNRI) Amisulpride (D2/3 antagonist) | Reboxetine: increased correlation between brainstem, and thalamus and PCC; and thalamus and accumbens; reduced correlation between putamen-brainstem; amygdala-ACC; and between the accumens and two regions of the ACC; reduced correlation between accumbens and two regions in ACC. Amisulpride: increased correlation between: PCC-brainstem; amygdala, brainstem and thalamus; putamen-brainstem. | |
| fMRI (humans) | Graph theoretic analysis Seed-based correlation | Atomoxetine (SNRI) | Reduced metrics of global correlation strength and clustering. Reduced correlation between FPN, and DMN and visual network, and reduced correlation between the visual and sensorimotor network. Reduced correlation within a set of occipital regions. Reduced correlation between early visual cortex and the rest of the brain. | |
| fMRI (rhesus macaque) | Dual regression | Atomoxetine (SNRI) | Reduced correlation within FPN, somatosensory, sensorimotor, visual, and superior temporal sulcus networks. Reduced correlation between various networks with an overall net change of reduced correlation. | |
| fMRI (rhesus macaque) | Graph-theoretic analysis | Atomoxetine (SNRI) | Reduced global efficiency. Reduced global correlation strength. Increased clustering. | |
| fMRI (humans) | Graph theoretic analysis and seed-based correlation | Pramipexole (D2 agonist) | Reduced correlation between caudate and nodes of the sensorimotor network. No change in topological metrics. | |
| fMRI (humans) | Graph theoretic analysis | Atomoxetine (SNRI) | Rest: reduced metrics of integration. N-back task: increased metrics of integration. | |
| fMRI (humans) | Generalized eigenvalue decomposition | Atomoxetine (SNRI) | Increased correlations in a network that loosely resembled a rlFPN, and distribution of β (negatively) and D2 receptors. Reduced correlations in a network that loosely resembled a llFPN, sensorimotor and DMN networks, and distribution of β (positively) and α1 receptors. | |
| MEG (humans) | DFA + computational model | Atomoxetine (SNRI) | Rest: reduced α scaling exponent due to atomoxetine. Task (bistable perception): reduced α scaling exponent due to atomoxetine. Computational model accounted for the findings as a change in excitation relative to inhibition. | |
| fMRI (humans) | Seed-based correlation Graph theoretic analysis | Phenylalanine and tyrosine depletion (DA depletion) | Reduced correlations strength in sensorimotor, salience, and temporal networks. Reduced between-module correlation of the sensorimotor and salience networks. | |
| MEG (humans) | Graph theoretic analysis + computational model | Atomoxetine (SNRI) | Rest: no effect of atomoxetine. Task (bistable perception): Atomoxetine increased correlation strength. Computational models indicate that effects can be accounted for by an increase in gain. | |
| fMRI (mice) | Graph theoretic analysis (FCD) Dual regression | Chemogenetic LC stimulation | Increase in global correlation strength. Increased correlation in the Salience, amygdala, auditory, striato-motor, and DMN networks. |
Summary of main findings of (pharmacological) manipulation of 5HT and Ach.
| fMRI (humans) | ICA-based back-reconstruction | Nicotine (nACh receptor agonist) | Reduced correlations within the DMN. Increased correlations within extrastriate cortex. | |
| fMRI (humans) | Seed-based correlation | Citalopram (SSRI) | Citalopram: reduced amygdala-vmPFC correlation. | |
| fMRI (humans) | Seed-based correlation | Citalopram (SSRI) | Reduced correlation between left dmPFC and left hippocampus. | |
| fMRI (humans) | Dual regression | Escitalopram (SSRI) | Reduced DMN correlations with PCC, ACC, hippocampus, and lateral parietal cortex. | |
| fMRI (humans) | Graph theoretic analysis (FCD) | Escitalopram (SSRI) | Reduced global strength of correlation. Local increases in thalamus and cerebellum. | |
| fMRI (humans) | Dual regression | Sertraline (SSRI) | Widespread decreases in correlation with DMN; executive control; visual and sensorimotor networks. Increased correlation between auditory network and PCC/precuneus. | |
| fMRI (humans) | Seed-based correlation | LSD (5HT agonist) | Increase in correlation between visual cortex and widespread regions of the cortex and between the parahippocampal cortex and the retrosplenial cortex and PCC, and increased correlations between parahippocampal cortex and dorsal mPFC and right dorsolateral PFC. | |
| fMRI (humans) | Graph theoretic analysis. Seed-based correlation | LSD (5HT agonist) | Increased global correlation strength. Brain regions that showed altered correlation strength overlapped with 5HT2A-r distributions. Increased correlation between four seeds (PFC, parietal cortex, precuneus, and thalamus) and sensorimotor areas. Reduced modularity. Increased participation coefficient of frontal and midline regions. Reduced rich-club coefficient. | |
| fMRI (humans) | Dual regression | Citalopram (SSRI) Galantamine (nACh receptor agonist) | Citalopram: reduction of correlations within the sensorimotor network, PFN, DMN, and executive control network. Galantamine: increased correlations between polar occipital network and distributed regions; between an auditory network and regions of the DMN and somatosensory cortex; reduced correlations within the DMN, and between DMN and lateral and inferior occipital cortices; between the FPN and DMN, inferior temporal and cerebellar regions. | |
| fMRI (humans) | Dynamic FC + computational model | LSD (5HT agonist) | The model captured the effect of 5HT2A-r stimulation as an increase in gain to explain the effect of LSD on the distribution of FC dynamics. | |
| fMRI (rhesus macaque) | Global signal correlation and dual regression | Pharmacological inactivation of basal forebrain | Broad reductions in coupling of local activity with the global signal, corresponding spatially to the inactivated location. Topography of individual RSNs unaffected. | |
| fMRI (humans) | Dynamic FC | Psilocybin (5HT agonist) | Longer dwell times for a global FC component. Reduced dwell times for FPN. | |
| fMRI (humans) | Graph theoretic analysis (FCD) Seed-based correlation | LSD (5HT agonist) | Reduced correlation (from positive toward zero) in associative networks. Increased correlation (from negative toward zero) in sensorimotor and thalamic networks. LSD effects correlated with 5HT2A-r distributions. Reduced correlation between sensorimotor areas and global signal. | |
| MEG (humans) | DFA + computational model | Donepezil (acetylcholinesterase inhibitor) | No effect of donepezil. | |
| MEG (humans) | Graph theoretic analysis + computational model | Donepezil (acetylcholinesterase inhibitor) | Rest: reduced correlation strength. Computational models indicate that effect can be accounted for by an increase in gain. | |
| fMRI, MUA, and LFP (mice) | GLM analysis | Blockwise optogenetic stimulation of DR | Wide suppression of cortical CBV response. Suppression of cortical MUA, and δ LFP power, which spatially correlated with the cortical CBV response. CBV response correlated with distribution of 5HT 1F, 2A, 2C receptors, but not 1A and 1B receptors. Correlations with receptor maps were stronger than correlation with DR projection profile. |